Biogen (XTER:IDP) Cyclically Adjusted PB Ratio: (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:IDP Biogen Inc XTER:IDP
55 GF Score
Price €189.92
GF Value €150.39
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen  (XTER:IDP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biogen Cyclically Adjusted PB Ratio Related Terms


Biogen Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted PB Ratio Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.93 3.96 3.32 1.79 1.88

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.52 1.88 1.90 2.18

XTER:IDP vs OGN, AMRN, NSRX: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


XTER:IDP
55GF Score
Biogen Inc XTER:IDP
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Biogen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=110.765/333.9520*333.9520
=110.765

Current CPI (Jun. 2026) = 333.9520.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201609 49.623 241.428 68.640
201612 53.282 241.432 73.700
201703 50.154 243.801 68.700
201706 48.767 244.955 66.485
201709 51.022 246.819 69.034
201712 50.392 246.524 68.263
201803 54.015 249.554 72.283
201806 52.101 251.989 69.048
201809 58.556 252.439 77.464
201812 58.123 251.233 77.260
201903 62.702 254.202 82.373
201906 62.031 256.143 80.874
201909 69.864 256.759 90.868
201912 68.937 256.974 89.587
202003 67.872 258.115 87.814
202006 63.437 257.797 82.177
202009 59.350 260.280 76.149
202012 57.714 260.474 73.995
202103 59.582 264.877 75.120
202106 59.853 271.696 73.568
202109 60.350 274.310 73.472
202112 65.600 278.802 78.576
202203 69.207 287.504 80.388
202206 77.351 296.311 87.177
202209 89.606 296.808 100.820
202212 87.831 296.797 98.826
202303 88.992 301.836 98.461
202306 92.216 305.109 100.933
202309 93.660 307.789 101.621
202312 93.658 306.746 101.965
202403 96.657 312.332 103.348
202406 102.011 314.175 108.432
202409 101.162 315.301 107.146
202412 109.552 315.605 115.921
202503 107.203 319.799 111.947
202506 104.288 322.561 107.971
202509 105.745 324.800 108.725
202512 106.208 324.054 109.452
202603 109.307 330.213 110.545
202606 110.765 333.952 110.765

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Biogen (XTER:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €189.92 is trading 26.3% above its estimated GF Value™ of €150.39. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for XTER:IDP:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €150.39 vs. price of €189.92 (26.3% above fair value)
  • GF Score™: 55/100 with 10 warning signs

No single metric tells the full story. See the XTER:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
55GF Score

Get the complete analysis for XTER:IDP

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€189.92
Price
€150.39
GF Value